Autres langues Processa Pharmaceuticals, Inc.

Actions

PCSA

US74275C4033

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 23/07/2026			Varia. 5j.	Varia. 1 janv.
2,870 ^USD	+12,99%		+28,12%	-0,35%

07/05	Processa Pharmaceuticals, Inc. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI
30/04	Processa Pharmaceuticals, Inc. annonce le changement de statut de Sian Bigora, Chief Development and Regulatory Officer, à compter du 1er mai 2026	CI

Autres langues

08/05	Processa Pharmaceuticals : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)
07/05	Processa Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
30/04	Processa Pharmaceuticals, Inc. Announces Transition of Employment Status of Sian Bigora, Chief Development and Regulatory Officer, Effective May 1, 2026
20/03	Bio-Path Holdings, Inc. Announces Scientific Advisory Board Appointments, Effective February 10, 2026
18/03	Processa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
18/03	Processa Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt
19/02	Processa Pharmaceuticals, Inc. Announces Expiration of Binding Term Sheet with Intact Therapeutics
12/01	Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference
05/01	Processa Pharmaceuticals, Inc. Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study
05/01	Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study
18/12	Wall Street Set to Open Higher Thursday as Inflation Rises Less Than Expected; Jobless Claims Decline
17/12	Top Midday Gainers
17/12	Processa Pharmaceuticals gives update on phase 2 study of metastatic breast cancer
17/12	Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer
17/12	Processa Pharmaceuticals, Inc. Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer
15/12	Processa Pharmaceuticals to effect 1-for-25 reverse stock split
06/11	Processa Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
05/11	Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025
05/11	Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 Pcs499 Study in Fsgs At Asn Kidney Week 2025
08/08/25	Peraso Inc. (NASDAQ: PRSO) Signals Turnaround - Reports Financials August 11, 2025 - More Stocks Inside
07/08/25	Processa Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025
07/08/25	Processa Pharmaceuticals secures strategic investment and evaluates corporate crypto treasury strategies
07/08/25	Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies
06/08/25	Processa Pharmaceuticals, Inc. announced that it has received $1.257452 million in funding
04/08/25	Processa Pharmaceuticals, Inc. announced that it expects to receive $1.257452 million in funding